Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Change in Account Payables (2018 - 2025)

Organogenesis Holdings has reported Change in Account Payables over the past 8 years, most recently at -$1.2 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$1.2 million for Q4 2025, down 132.08% from a year ago — trailing twelve months through Dec 2025 was -$528000.0 (up 77.74% YoY), and the annual figure for FY2025 was -$528000.0, up 77.74%.
  • Change in Account Payables for Q4 2025 was -$1.2 million at Organogenesis Holdings, down from -$994000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for ORGO hit a ceiling of $4.5 million in Q3 2021 and a floor of -$4.4 million in Q1 2024.
  • Median Change in Account Payables over the past 5 years was -$1.1 million (2021), compared with a mean of $204950.0.
  • Biggest five-year swings in Change in Account Payables: soared 442.54% in 2022 and later tumbled 2975.4% in 2024.
  • Organogenesis Holdings' Change in Account Payables stood at -$1.4 million in 2021, then tumbled by 43.96% to -$2.0 million in 2022, then skyrocketed by 277.56% to $3.6 million in 2023, then rose by 2.73% to $3.6 million in 2024, then tumbled by 132.08% to -$1.2 million in 2025.
  • The last three reported values for Change in Account Payables were -$1.2 million (Q4 2025), -$994000.0 (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.